Anzeige
Mehr »
Donnerstag, 14.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PCBM | ISIN: US0144421072 | Ticker-Symbol: 0Z2
Tradegate
13.08.25 | 18:32
1,800 Euro
-3,74 % -0,070
1-Jahres-Chart
ALECTOR INC Chart 1 Jahr
5-Tage-Chart
ALECTOR INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8601,88013.08.
1,8301,88013.08.

Aktuelle News zur ALECTOR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.Alector: EPS übertrifft Schätzungen um 0,17 $ - Umsatz besser als erwartet8
ALECTOR Aktie jetzt für 0€ handeln
07.08.Alector, Inc. - 10-Q, Quarterly Report2
07.08.Alector, Inc. - 8-K, Current Report1
28.07.Alector upgraded at Mizuho on high risk/higher-reward2
28.07.Mizuho upgrades Alector stock to Outperform on FTD drug prospects2
13.06.Alector, Inc.: Alector Provides Executive Leadership Update168-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector...
► Artikel lesen
13.06.Alector, Inc. - 8-K, Current Report1
28.03.Alector, Inc.: Alector Provides Executive Leadership Update303--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
10.03.Alector, Inc. - 8-K, Current Report2
26.02.Alector, Inc.: Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update249Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226...
► Artikel lesen
26.02.Alector, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Alector, Inc. - 10-K, Annual Report-
26.02.Alector, Inc. - 8-K, Current Report2
25.02.Alector Q4 2024 Earnings Preview1
13.01.Alector, Inc.: Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025219Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated...
► Artikel lesen
25.11.24Alector, Inc.: Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update205SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment...
► Artikel lesen
06.11.24Alector, Inc.: Alector Reports Third Quarter 2024 Financial Results and Provides Business Update139Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1